Clinically Bharat

We Can Cover You

Healthcare

EU top court backs Illumina fight against EU probe into Grail deal, ET HealthWorld

Email :74

Brussels: Europe’s top court on Tuesday backed U.S. gene sequencing company Illumina’s fight against EU antitrust regulators’ investigation into its $7.1 billion bid for cancer diagnostic test maker Grail .

“The Court of Justice sets aside the judgment of the General Court and annuls the decisions by which the Commission accepted requests from national competition authorities seeking the examination of the proposed concentration,” the Luxembourg-based Court of Justice of the European Union (CJEU) said.

The General Court had in 2022 ruled in favour of the European Commission.

Illumina, which founded Grail and spun it off in 2016 only to re-acquire it in 2021 for $7.1 billion, had fought against the European Commission’s rarely used power called Article 22 to assess the deal even though it was below the EU merger revenue threshold.

The cases are Cases C-611/22 P Illumina v Commission and C-625/22 P Grail v Commission. (Reporting by Foo Yun Chee)

  • Published On Sep 3, 2024 at 02:35 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post